Healthcare dealmaking has been defined all year by a familiar pattern: large pharmaceutical companies acquiring clinical-stage biotechs to offset more than $300 billion in prescription drug revenue set to lose patent exclusivity by 2030. That pattern held through the first half of 2026, with biopharma M&A topping $65 billion in the first quarter alone.
Early August brought a different kind of deal. A private equity-backed carve-out of device manufacturing capacity, priced at roughly three times revenue, points to sponsors now targeting the infrastructure behind medical devices rather than the drug pipelines themselves — the third sizable healthcare take-private in quick succession.
What changed: with pipeline-focused targets increasingly bid up, some buyers are moving a step back in the value chain toward manufacturing and infrastructure assets that support multiple therapeutic programs at once.
Why it matters: for strategics, infrastructure assets offer a way to add value without competing directly for the same scarce late-stage biotech targets. For sponsors, it’s a new category of platform investment with less binary clinical-trial risk than a single-asset biotech bet.
What to watch: whether more sponsors follow this playbook into device and drug manufacturing infrastructure, and whether valuations there begin to climb toward pipeline-asset multiples.
Source: BioBucks Biotech M&A Tracker, MobiHealthNews.
